Jagsonpal Pharmaceuticals Limitedconsolidated revenue +29% to ₹96 Cr, two deals

Jagsonpal Pharmaceuticals' Q2 FY27 call, held on 29 October 2026, delivered its first consolidated results after taking control of Aequitas, a hospital-channel business, in July.

Consolidated revenue was ₹96 crore, up 29%, and standalone revenue was ₹81 crore, up 9.3%. Standalone EBITDA margin was 22.7% and consolidated 19.3%, with standalone profit after tax of ₹13 crore and cash above ₹135 crore. The company also took on Group Pharma's wellness brands from 1 October, lifting doctor reach to about 1,37,000. Management called organic growth of 9.3% in the first half short of its potential, and analysts questioned the gap to the roughly 15% shown by Pharmarack data.

It targets quarterly revenue above ₹100 crore and EBITDA-accretive growth in Q3, a consolidated margin near 22%, and ₹500 crore of revenue by 2028 from the current basket without further acquisitions. Aequitas cost fixes show from Q4, and an organic versus inorganic split will come in the Q3 commentary.